期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

表皮生长因子受体抑制剂耐药研究进展 被引量：3

下载PDF
导出
摘要 EGFR(表皮生长因子受体)抑制剂现已在临床中广泛使用,不论是单用还是与化疗药物联合使用都表现出了较强的作用,延长了患者的生存时间,改善了患者的生存质量,但由于最终几乎所有的患者都会产生耐药,限制了其长期疗效。因此,对其耐药机制的研究对于阐明耐药机理、克服耐药以及研发新的抗肿瘤药物都具有非常重要的意义。EGFR抑制剂耐药的机制主要包括以下几个方面:酪氨酸受体高表达,下游效应蛋白活化;非依赖于EGFR的血管生成增加;下游区介质活化,信号途径激活以及EGFR激酶区域特异性继发突变。现就EGFR抑制剂耐药机制研究进展综述如下:酪氨酸受体高表达,下游效应蛋白活化细胞内存在许多转导增殖刺激的酪氨酸激酶(tyrosine kinase,TK)受体,包括EGFR、胰岛素样生长因子1受体(IGF-1R:insulin-like growth factor-Ireceptor)、VEGFR、血小板衍生生长因子受体(PDG-FR)以及肝细胞生长因子受体(c-MET)。其中,IGF-1R途径是相当重要的一条途径。人IGF-1R是一种跨膜的酪氨酸蛋白受体,对细胞的分裂分化和增殖具有重要的调控作用。IGF-1R与其配体结合通过启动2条...
作者 陈萍 李慧艳 侯梅
机构地区 四川大学华西医院肿瘤中心
出处 《肿瘤预防与治疗》 2009年第1期81-83,56,共4页 Journal of Cancer Control And Treatment
关键词 EGFR抑制剂 耐药
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Hidetaka Uramoto,Kenji Sugio,Tsunehiro Oyama,Masakazu Sugaya,Takeshi Hanagiri,Kosei Yasumoto.Resistance to gefitinib[J].International Journal of Clinical Oncology.2006(6)
  • 2Baoli Qin,Hiroshi Ariyama,Eishi Baba,Risa Tanaka,Hitoshi Kusaba,Mine Harada,Shuji Nakano.Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells[J].Cancer Chemotherapy and Pharmacology.2006(5)
  • 3Festuccia C,,Gravina GL,Millimaggi D,et al.Uncoupling of the epidermal growth factor receptor from downstream signal transduc-tion molecules guides the acquired resistance to gefitinib in prostate cancer cells[].Oncology Reports.2007
  • 4Timpson P,Wilson AS,Lehrbach GM,et al.Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is as-sociated with enhanced cell proliferation and resistance to the epi-dermal growth factor receptor inhibitor gefitinib[].Cancer Research.2007
  • 5Uramoto H,Sugio K,Oyama T,et al.Resistance to gefitinib[].International Journal of Clinical Oncology.2006
  • 6Ogino A,Kitao H,Hirano S,et al.Emergence of epidermal growth factor receptor T790Mmutation during chronic exposure to gefitinib in a non small cell lung cancer cell line[].Cancer Research.2007
  • 7Carter TA,Wodicka LM,Shah NP,et al.Inhibition of drug-re-sistant mutants of ABL,KIT,and EGF receptor kinases[].Pro-ceedings of the National Academy of Sciences of the United States of America.2005
  • 8Qin B,Ariyama H,Baba E,et al.Activated Src and Ras induce gefitinib resistance by activation of signaling pathways down-stream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells[].Cancer Chemother.2006
  • 9Normanno,N,De,Luca,A,Maiello,MR,Campiglio,M,Napolitano,M,Mancino,M,Carotenuto,A,Viglietto,G,Menard,S.The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib[].Journal of Cellular Physiology.2006
  • 10Kobayashi S,Shimamura T,Monti S, et al.Transcriptional profiling identifies Cyclin D1 as a critical downstream effector of mutant epidermal growth fac- tor receptor signaling[].Cancer Research.2006

同被引文献32

  • 1卢昕,胡安斌,张勇,陈立波,郑启昌.靶向survivin的siRNA对肝癌细胞生物学行为的影响[J].世界华人消化杂志,2004,12(7):1534-1538. 被引量：4
  • 2Agelaki S,G eorgoulias V.Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer[J].Expert Opin Emerging Drugs,2005,10(4):855-874.
  • 3Wang L,Zhang GM,Feng ZH.Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line[J].Acta Pharmacol Sin,2003,24(12):1235-1240.
  • 4Estève PO,Chin HG,Pradhan S.Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells[J].J Biol Chem,2007,282(4):2615-2625.
  • 5Yao LL,Wang YG,Cai WJ,et al.Survivin mediates the anti-apoptotic effect of delta-opioid receptor stimulation in cardiomyocytes[J].J Cell Sci,2007,120(5):895-907.
  • 6Zhou JB,Bi CL,Jaainghe VJ,et al.Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML[J].Blood,2009,1 13 (17):40524062.
  • 7Lu J,Tan M,Huang WC,et al.Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance[J].Clin Cancer Res,2009,15(4):1326-1334.
  • 8Belani C P, Goss G, Blumenschein G Jr. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC) [J]. Cancer Treat Rev, 2012, 38(3): 173-184.
  • 9Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as main- tenance treatment in advanced non-small-cell lung cancer: amulticentre, randomized, placebo- controlled phase 3 study [J]. Lanct Oncol, 2010, 11 (6): 521-529.
  • 10P6rol M, Chouaid C, P6rol D, et al. Randomized, phase 111 study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treat- ment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer [J]. J Clin Oncol, 2012, 30(28): 3516-3524.

引证文献3

二级引证文献3

肿瘤预防与治疗
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部